The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

Innate Pharma to Present Phase 2 Lung Cancer Trial Results at AACR 2026

Key Facts

1Innate Pharma will present interim results from the MATISSE Phase 2 study of IPH5201 at the AACR Annual Meeting 2026.

2The study evaluates IPH5201 in combination with durvalumab and chemotherapy for resectable non-small cell lung cancer (NSCLC).

Innate Pharma SA has announced that interim results from the MATISSE Phase 2 study of IPH5201 will be presented during a plenary session at the AACR Annual Meeting 2026. The clinical trial evaluates the efficacy of IPH5201 in combination with durvalumab and chemotherapy for patients with resectable non-small cell lung cancer (NSCLC). Being selected for a plenary session at a major medical conference is a significant milestone, signaling strong clinical progress and potential for the immunotherapy combination. The study is conducted in partnership with AstraZeneca, further validating the strategic importance of the candidate. Investors are closely monitoring the upcoming data release, as the presentation is viewed as a bullish indicator for the company's oncology pipeline. The market impact will likely depend on the specific efficacy and safety metrics revealed during the session.